145 related articles for article (PubMed ID: 22289674)
1. Meta-analysis: comparative efficacy of H2-receptor antagonists and proton pump inhibitors for reducing aspiration risk during anaesthesia depending on the administration route and schedule.
Puig I; Calzado S; Suárez D; Sánchez-Delgado J; López S; Calvet X
Pharmacol Res; 2012 Apr; 65(4):480-90. PubMed ID: 22289674
[TBL] [Abstract][Full Text] [Related]
2. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough.
Mainie I; Tutuian R; Castell DO
J Clin Gastroenterol; 2008 Jul; 42(6):676-9. PubMed ID: 18496394
[TBL] [Abstract][Full Text] [Related]
3. Does long-term medication with a proton pump inhibitor induce a tolerance to H2 receptor antagonist?
Hashimoto H; Kushikata T; Kudo M; Hirota K
J Gastroenterol; 2007 Apr; 42(4):275-8. PubMed ID: 17464455
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a single 24-hour pre-anesthetic dose of proton pump inhibitors.
Hirota K; Imai A; Kudo M; Hashimoto H; Kushikata T
J Gastroenterol Hepatol; 2009 Jul; 24(7):1244-7. PubMed ID: 19486452
[TBL] [Abstract][Full Text] [Related]
5. Interaction of magnesium oxide with gastric acid secretion inhibitors in clinical pharmacotherapy.
Yamasaki M; Funakoshi S; Matsuda S; Imazu T; Takeda Y; Murakami T; Maeda Y
Eur J Clin Pharmacol; 2014 Aug; 70(8):921-4. PubMed ID: 24820768
[TBL] [Abstract][Full Text] [Related]
6. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
Van De Sijpe G; Beuselinck B; Van Nieuwenhuyse T; Poncelet R; Bechter O; Albersen M; Roussel E; Baldewijns M; Tack J; Spriet I
Eur J Clin Pharmacol; 2020 Sep; 76(9):1273-1280. PubMed ID: 32474662
[TBL] [Abstract][Full Text] [Related]
7. Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib.
Lam LH; Capparelli EV; Kurzrock R
Cancer Chemother Pharmacol; 2016 Aug; 78(2):427-32. PubMed ID: 27372908
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Harris RA; Kuppermann M; Richter JE
Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis.
Pongprasobchai S; Kridkratoke S; Nopmaneejumruslers C
J Med Assoc Thai; 2009 May; 92(5):632-7. PubMed ID: 19459523
[TBL] [Abstract][Full Text] [Related]
10. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough.
Fackler WK; Ours TM; Vaezi MF; Richter JE
Gastroenterology; 2002 Mar; 122(3):625-32. PubMed ID: 11874994
[TBL] [Abstract][Full Text] [Related]
11. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
Takahashi N; Miura M; Niioka T; Sawada K
Cancer Chemother Pharmacol; 2012 Apr; 69(4):999-1004. PubMed ID: 22147077
[TBL] [Abstract][Full Text] [Related]
12. The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials.
Rostom A; Wells G; Tugwell P; Welch V; Dubé C; McGowan J
J Rheumatol; 2000 Sep; 27(9):2203-14. PubMed ID: 10990235
[TBL] [Abstract][Full Text] [Related]
13. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial.
Uedo N; Takeuchi Y; Yamada T; Ishihara R; Ogiyama H; Yamamoto S; Kato M; Tatsumi K; Masuda E; Tamai C; Yamamoto S; Higashino K; Iishi H; Tatsuta M
Am J Gastroenterol; 2007 Aug; 102(8):1610-6. PubMed ID: 17403076
[TBL] [Abstract][Full Text] [Related]
14. Do proton pump inhibitors increase the incidence of nosocomial pneumonia and related infectious complications when compared with histamine-2 receptor antagonists in critically ill trauma patients?
Mallow S; Rebuck JA; Osler T; Ahern J; Healey MA; Rogers FB
Curr Surg; 2004; 61(5):452-8. PubMed ID: 15475094
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of H2 receptor antagonists for prevention of upper gastrointestinal bleeding during dual-antiplatelet therapy.
Yasu T; Sato N; Kurokawa Y; Saito S; Shoji M
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):854-60. PubMed ID: 24040853
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of preanesthetic proton pump inhibitor treatment for patients on long-term H2 antagonist therapy.
Hirota K; Kudo M; Hashimoto H; Kushikata T
Anesth Analg; 2005 Oct; 101(4):1038-1041. PubMed ID: 16192516
[TBL] [Abstract][Full Text] [Related]
17. Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung Cancer.
Yokota H; Sato K; Okuda Y; Kobayashi H; Takeda M; Asano M; Ito H; Miura M
Clin Lung Cancer; 2017 Nov; 18(6):e433-e439. PubMed ID: 28579188
[TBL] [Abstract][Full Text] [Related]
18. Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease.
Juillerat P; Schneeweiss S; Cook EF; Ananthakrishnan AN; Mogun H; Korzenik JR
Aliment Pharmacol Ther; 2012 Aug; 36(3):239-47. PubMed ID: 22670722
[TBL] [Abstract][Full Text] [Related]
19. Fracture risk of young adults receiving proton-pump inhibitors and H2-receptor antagonists.
Fedida B; Schermann H; Ankory R; Rotman D; Shichman I; Yoffe V; Shlaifer A; Luger E
Int J Clin Pract; 2019 May; 73(5):e13339. PubMed ID: 30829427
[TBL] [Abstract][Full Text] [Related]
20. Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study.
Kim B; Jung JH; Han K; Kang S; Lee E; Chung H; Kim SG; Cho SJ
J Korean Med Sci; 2023 Apr; 38(13):e99. PubMed ID: 37012686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
